You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Assessing Current Practice in the Diagnosis and Management of Alpha-Gal Syndrome

  • Authors: Scott P. Commins, MD, PhD
  • CME / ABIM MOC / CE Released: 3/6/2023
  • Valid for credit through: 3/6/2024
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    Nurses - 0.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for emergency medicine physicians, primary care physicians, pediatricians, nurses/nurse practitioners, dietitians, and nutritionists.

The goal of this activity is for learners to be better able to self-assess gaps in their knowledge regarding the diagnosis and management of patients with alpha-gal syndrome (AGS).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical management of patients with AGS in an interprofessional environment
  • Self-assess learning needs related to
    • Testing and workup of patients with AGS


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Scott P. Commins, MD, PhD

    Associate Professor
    Medicine and Pediatrics
    Associate Chief
    Allergy and Immunology
    Medical Director
    UNC Allergy and Immunology Clinic
    Chapel Hill, North Carolina


    Scott P. Commins, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: F. Hoffmann-La Roche Ltd
    Speaker or member of speakers bureau for: Genentech, Inc.


  • Karen Badal, MD, MPH

    Senior Medical Education Director, Medscape, LLC


    Karen Badal, MD, MPH, has no relevant financial relationships.

  • Megan Breuer, PhD

    Medical Writer, Medscape, LLC


    Megan Breuer, PhD, has the following relevant financial relationships:
    Consultant/advisor for Paratek Pharmaceuticals, Inc (former); Owns stock in (publicly traded) Bristol Myers Squibb Company; Johnson & Johnson; Paratek Pharmaceuticals Inc, Vertex Pharmaceuticals Inc.

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit(s)™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Assessing Current Practice in the Diagnosis and Management of Alpha-Gal Syndrome

Authors: Scott P. Commins, MD, PhDFaculty and Disclosures

CME / ABIM MOC / CE Released: 3/6/2023

Valid for credit through: 3/6/2024



  1. Carson AS, et al. Where's the beef? Understanding allergic responses to red meat in alpha-gal syndrome. J Immunol. 2022:208:267-277.
  2. Binder AM, et al. Diagnostic testing for galactose-alpha-1,3-galactose, United States, 2010 to 2018. Ann Allergy Asthma Immunol. 2021;126:411-416.
  3. Commins SP. Diagnosis & management of alpha-gal syndrome: lessons from 2,500 patients. Expert Rev Clin Immunol. 2020;16:667-677.
  4. Platts-Mills TAE, et al. Diagnosis and management of patients with the α-gal syndrome. J Allergy Clin Immunol Pract. 2020;8:15-23.
  5. Macdougall JD, et al. The meat of the matter: understanding and managing alpha-gal syndrome. Immunotargets Ther. 2022;11:37-54.
  6. De la Fuente, J, et al. Alpha-gal syndrome: challenges to understanding sensitization and clinical reactions to alpha-gal. Expert Rev Mol Diagn. 2020;20:905-911.
  7. Rutkowski K, et al. Alpha‐gal syndrome: an emerging cause of food and drug allergy. Clin Exp Allergy. 2020;50:894-903.
  8. Saretta F, et al. Alpha-gal syndrome in children: peculiarities of a "tick-borne" allergic disease. Front Pediatr. 2021;9:801753.
  9. Patel C, et al. 'Doc, will I ever eat steak again?': diagnosis and management of alpha-gal syndrome. Curr Opin Pediatr. 2020;32:816-824.
  10. Vaz-Rodrigues R, et al. Current and future strategies for the diagnosis and treatment of the alpha-gal syndrome (AGS). J Asthma Allergy. 2022;15:957-970.
  11. Pollack K, et al. α-Gal syndrome vs chronic urticaria. JAMA Dermatol. 2019;155:115-116.
  12. Fischer J, et al. Prevalence and impact of type I sensitization to alpha-gal in patients consulting an allergy unit. Int Arch Allergy Immunol. 2020;181:119-127.
  13. Centers for Disease Control and Prevention (CDC). Preventing tick bites: on people. Accessed December 20, 2022.
  14. Chung CH, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008;358:1109-1117.
  15. Commins SP. Invited commentary: alpha-gal allergy: tip of the iceberg to a pivotal immune response. Curr Allergy Asthma Rep. 2016;16:61.
  16. Mabelane T, et al. Ingestion of mammalian meat and alpha-gal allergy: clinical relevance in primary care. Afr J Prim Health Care Fam Med. 2019;11:e1-e5.
  17. Croglio MP, et al. Isolated gastrointestinal alpha-gal meat allergy is a cause for gastrointestinal distress without anaphylaxis. Gastroenterology. 2021;160:2178-2180.
« Return to: Assessing Current Practice in the Diagnosis and Management of Alpha-Gal Syndrome
  • Print